Moderna stock slips 1.05% ahead of November 6 results
Published on 11/05/2026 at 16:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey Tests Before Moderna Results
- Third-quarter results are scheduled before the US market opens on Friday, November 6.
- Melanoma data have strengthened the oncology case but do not yet create commercial revenue.
- The report will put vaccine demand, spending and management's outlook in focus.
Moderna stock traded at 217.88 euros on Lang & Schwarz at 16:41 CET on Thursday, November 5, 2026, 1.05 percent below the Xetra close of 220.20 euros on Wednesday, November 4. The latest quote is 5.09 percent above the 207.33-euro quote in the relevant previous report published on November 4 at 13:43.
Results Set The Next Checkpoint
Moderna is scheduled to report third-quarter results before the US market opens on Friday, November 6. The update will give investors a fresh read on vaccine demand, research spending and management's near-term outlook.
The previous relevant report said analysts expected quarterly revenue of 888.8 million US dollars and a loss of 1.37 US dollars per share. Those expectations put seasonal respiratory sales and cost control at the center of the next market test.
Oncology Offers Longer-Term Potential
Moderna and Merck's late-stage melanoma data strengthened the case for the companies' personalized vaccine and Keytruda combination. The treatment reduced the risk of recurrence or death by 42 percent in the reported results, but the program still faces regulatory, manufacturing and commercial hurdles.
The clinical progress therefore improves the oncology narrative without creating immediate revenue. Investors must weigh that longer-term opportunity against the company's dependence on respiratory products and the financial performance due in the next report.
The Xetra reference for the euro listing is reported by De Belegger, which identifies the listing as 0QF.XETRA and gives the November 4 close at 220.20 euros.
Follow the real-time quote of Moderna stock for further trading updates.
Moderna operates in the broader market context of the S&P 500.
More news and analyses on Moderna stock will follow as the earnings report and oncology developments add new information for investors.
Moderna Inc. Key Facts
- Company: Moderna Inc.
- ISIN: US60770K1079
- Ticker: MRNA
- Lang & Schwarz quote: 217.88 euros, Thursday, November 5, 2026, at 16:41 CET
- Xetra close: 220.20 euros, Wednesday, November 4, 2026
- Next event: Third-quarter results before the US market opens on Friday, November 6, 2026
